Stephens Inc’s abrdn Life Sciences Investors HQL Stock Holding History

Stephens Inc’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$631K	Buy	31,510 +1,093	+4%	+$19.3K	0.01%	809
2026 Q1	$495K	Buy	30,417 +6,548	+27%	+$109K	0.01%	853
2025 Q4	$401K	Hold	23,869	–	–	0.01%	926
2025 Q3	$370K	Buy	23,869 +2,638	+12%	+$36.1K	﹤0.01%	955
2025 Q2	$272K	Buy	21,231 +1,895	+10%	+$23.4K	﹤0.01%	1056
2025 Q1	$245K	Buy	19,336 +6,947	+56%	+$94.1K	﹤0.01%	1068
2024 Q4	$163K	Sell	12,389 -318	-3%	-$4.59K	﹤0.01%	1182
2024 Q3	$192K	Buy	12,707 +896	+8%	+$13.6K	﹤0.01%	1200
2024 Q2	$167K	Sell	11,811 -348	-3%	-$4.71K	﹤0.01%	1188
2024 Q1	$166K	Sell	12,159 -677	-5%	-$9.37K	﹤0.01%	1182
2023 Q4	$173K	Buy	12,836 +1,288	+11%	+$15.8K	﹤0.01%	1109
2023 Q3	$144K	Sell	11,548 -95	-0.8%	-$1.25K	﹤0.01%	1081
2023 Q2	$158K	Buy	11,643 +236	+2%	+$3.26K	﹤0.01%	1097
2023 Q1	$159K	Sell	11,407 -2,518	-18%	-$36K	﹤0.01%	1062
2022 Q4	$198K	Sell	13,925 -77,220	-85%	-$1.12M	﹤0.01%	1010
2022 Q3	$1.25M	Buy	91,145 +48,168	+112%	+$720K	0.03%	475
2022 Q2	$612K	Buy	42,977 +32,549	+312%	+$492K	0.01%	659
2022 Q1	$172K	Sell	10,428 -55,139	-84%	-$949K	﹤0.01%	1191
2021 Q4	$1.26M	Sell	65,567 -52,416	-44%	-$1.05M	0.02%	557
2021 Q3	$2.45M	Buy	117,983 +1,898	+2%	+$40.6K	0.04%	413
2021 Q2	$2.49M	Buy	116,085 +99,524	+601%	+$2.01M	0.04%	429
2021 Q1	$326K	Buy	16,561 +913	+6%	+$18.8K	0.01%	974
2020 Q4	$309K	Buy	15,648 +626	+4%	+$11.6K	0.01%	908
2020 Q3	$264K	Buy	15,022 +2,084	+16%	+$37.3K	0.01%	929
2020 Q2	$232K	Buy	+12,938	New	+$222K	0.01%	919
2019 Q1	–	Sell	-30,061	Closed	-$454K	–	1192
2018 Q4	$454K	Sell	30,061 -1,182	-4%	-$20.8K	0.01%	728
2018 Q3	$638K	Buy	31,243 +7,211	+30%	+$143K	0.02%	711
2018 Q2	$452K	Buy	24,032 +731	+3%	+$13.8K	0.01%	625
2018 Q1	$448K	Buy	23,301 +10,375	+80%	+$208K	0.02%	517
2017 Q4	$254K	Sell	12,926 -55,058	-81%	-$1.1M	0.01%	600
2017 Q3	$1.46M	Buy	+67,984	New	+$1.44M	0.05%	316

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Stephens Inc's HQL Position: Q2 2026 in Review

Stephens Inc increased its abrdn Life Sciences Investors (HQL) stake by 3.6% in Q2 2026, buying an estimated $19.3K and bringing the position to 31,510 shares worth $631K. The position accounts for 0.01% of the portfolio, ranked #809.

Stephens Inc first reported a position in HQL in Q3 2017 and has held it in 31 quarters since. The position peaked at $2.49M in Q2 2021. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Stephens Inc held 31,510 shares of abrdn Life Sciences Investors worth $631K as of Q2 2026.
Stephens Inc bought 1,093 abrdn Life Sciences Investors shares in Q2 2026, an estimated $19.3K.
abrdn Life Sciences Investors made up 0.01% of Stephens Inc's portfolio in Q2 2026, its #809 holding.
Stephens Inc first reported a position in abrdn Life Sciences Investors in Q3 2017 and has held it in 31 quarters since.
Stephens Inc's abrdn Life Sciences Investors position peaked at $2.49M in Q2 2021.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Stephens Inc's 13F filing for Q2 2026, filed 29 Jul 2026.